Short answer
Apogee Therapeutics, Inc. (APGE) filed an 8-K current report with the SEC on May 27, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Boilerplate Regulation FD disclosure language only.
Apogee Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Boilerplate Regulation FD disclosure language only
- No substantive company update or investor-actionable information in the provided excerpt
Item 8.01 · Other Events
- Phase 2 APEX Part B met its primary endpoint; mid-dose EASI-75 reached 65.9% versus 23.4% placebo at Week 16
- Mid-dose also improved IGA 0/1 to 46.0%, EASI-90 to 47.4%, and itch response to 50.5% versus placebo
- Planned Phase 3 mid-dose showed 10.6% conjunctivitis versus 20.7% at high-dose, supporting dose selection
- Phase 3 ADventure trials planned for 2H 2026, subject to regulatory interactions, with potential AD launch anticipated in 2029
- Key investment risks include Phase 3 execution, regulatory feedback, durability data, and funding through multiple indications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Apogee Therapeutics, Inc. 8-K filings
Get the next APGE 8-K as it lands
Follow APGE for push alerts, or ask the research agent what this filing means.